Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$47.30 USD

47.30
1,123,192

+0.37 (0.79%)

Updated May 17, 2024 04:00 PM ET

After-Market: $47.32 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (140 out of 249)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline

Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).

Sanghamitra Saha headshot

Beyond Earnings Growth: Focus on Beat With These 5 Stocks

Inside the top-ranked stocks that can beat earnings estimates in their next release.

Tandem (TNDM) Q2 Loss Narrower Than Expected, Sales Top Mark

Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.

Zacks.com featured highlights include: Crocs, IAC/InterActive, Fortinet, Tandem Diabetes and Cross Country

Zacks.com featured highlights include: Crocs, IAC/InterActive, Fortinet, Tandem Diabetes and Cross Country

Sanghamitra Saha headshot

5 Top-Ranked Stocks Primed for an Earnings Beat

Inside the top-ranked stocks that can beat earnings estimates in their next releases.

The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center

The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center

Nalak Das headshot

5 Top Picks on Three Key Takeaways From Q2 U.S. GDP

A closer look at the second-quarter GDP will help us to make three important inferences, which are expected to give guidance on the economy and stock market in the near term.

Can IDEXX's (IDXX) International Growth Drive Q2 Earnings?

In the United States, IDEXX (IDXX) witnesses a strong uptrend in CAG Diagnostic recurring revenues.

Tandem Diabetes (TNDM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tandem Diabetes (TNDM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tandem Releases Positive Results Of t:slim X2 Pump Studies

The results of the studies are a major breakthrough for Tandem (TNDM) in the field of diabetes treatment.

Why Is Tandem Diabetes (TNDM) Up 9.7% Since Last Earnings Report?

Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to Tandem (TNDM) Stock for Now

Investor confidence in Tandem Diabetes (TNDM) is still high on several positive factors.

Tandem's (TNDM) Q1 Loss Wider Than Expected, Sales Top Mark

Tandem's (TNDM) introduction of t:slim X2 with Basal-IQ technology, ramped-up supply capacity along with its global launch, substantially drive its top line in Q1.

Will Tandem Diabetes (TNDM) Report Negative Earnings Next Week? What You Should Know

Tandem Diabetes (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Tandem Diabetes' (TNDM) Q1 Earnings?

The roll-out of Tandem Diabetes' (TNDM) unique insulin pump platform viz. t:slim X2 with Basal-IQ technology is expected to drive the top line in first-quarter 2019.

Tandem Diabetes (TNDM) Outpaces Stock Market Gains: What You Should Know

Tandem Diabetes (TNDM) closed at $62.37 in the latest trading session, marking a +0.68% move from the prior day.

Tandem Diabetes (TNDM) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Tandem Diabetes (TNDM) closed at $63.76, marking a +1.21% move from the previous day.

Why Is Tandem Diabetes (TNDM) Up 1.8% Since Last Earnings Report?

Tandem Diabetes (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tandem Diabetes (TNDM) Hits a 52-Week High on Solid Prospects

Tandem Diabetes Care's (TNDM) growth in pump shipments drives the top line significantly.

Tandem Diabetes Signs as an Insulin Pump Vendor in Canada

Tandem Diabetes' (TNDM) insulin pump seems to be a strategic fit and well-timed from its massive uptake by the diabetic patients in Canada.

Tandem's Global Growth a Boost, Operating Losses a Bane

Tandem's (TNDM) t:slim X2 Insulin Pump clinching a commercial license in Canada during Q4 is a tailwind.

Here's Why You Should Invest in Chemed (CHE) Stock Right Now

Chemed (CHE) sees revenue growth across its wholly-owned subsidiaries, VITAS Healthcare and Roto-Rooter. Its capital deployment policy is based on buyouts and solid return of cash to shareholders.

Tandem (TNDM) Posts Earnings in Q4, Revenues Top Estimates

The roll-out of t:slim X2 with Basal-IQ technology, increased supply capacity and renewal sales, as well as the international launch, drive Tandem's (TNDM) Q4 revenues.